Product development

Citryll, is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity. The latter are the MoAs of the current medicines like anti-TNF antibodies, small molecule Jak inhibitors and antagonists of B cell biology like anti-CD20 antibodies.

Citryll’s lead programme, targets the formation of neutrophil extracellular traps, called NETs and its pathological consequences.

Citryll BV is a private pharmaceutical company that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.


Area of work

Drug discovery, Drug development

“Targeting the pathobiology of neutrophil extracellular traps”

News from Citryll

Pivot Park: a unique ecosystem

22 Sep 21

Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

17 Aug 21

Citryll announced that it has recently secured three grant of patents

21 Jul 21